| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 23 Apr 2025 | 8 Apr 2025 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 inter alia to consider and approve the audited standalone and consolidated financial results for the quarter and year ending March 31 2025; and to consider the recommendation of final dividend if any. Outcome of the Board Meeting - April 23, 2025. (As Per BSE Announcement Dated on:23.04.2025) | ||
| Board Meeting | 23 Jan 2025 | 13 Jan 2025 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ending December 31 2024 amongst other routine matters. Outcome of the Board Meeting - January 23, 2025 (As Per BSE Announcement Dated on: 23/01/2025) | ||
| Board Meeting | 23 Oct 2024 | 4 Oct 2024 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ending September 30 2024 amongst other routine matters. Outcome of the Board Meeting - October 23, 2024. (As Per BSE Announcement dated on 23.10.2024) | ||
| Board Meeting | 24 Jul 2024 | 28 Jun 2024 |
| Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ending June 30 2024 amongst other routine matters Outcome of the Board Meeting - July 24, 2024. (As per BSE Announcement Dated on 24/07/2024) | ||
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
